MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, SAGE had -$13,534K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$13,534K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Stock-based compensation expense
15,660
Net loss
-111,866
Amortization of discount on marketable securities
1,423
Prepaid expenses and other current assets
1,389
Other receivable
8,105
Other long-term assets
-1,072
Accrued expenses and other liabilities
-15,526
Collaboration receivable - related party
7,136
Accounts payable
-12,007
Depreciation expense
216
Premium on marketable securities
295
Right-of-use operating asset
-796
Operating lease liabilities, non-current
-975
Operating lease liabilities, current
560
Net cash used in operating activities
-140,418
Proceeds from sales and maturities of marketable securities
283,376
Purchases of marketable securities
156,575
Net cash provided by investing activities
126,801
Proceeds from stock option exercises and employee stock purchase plan issuances
242
Payment of employee tax obligations related to vesting of restricted stock units
159
Net cash provided by financing activities
83
Net increase (decrease) in cash, cash equivalents and restricted cash
-13,534
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics, Inc. (SAGE)